ERBB2 and breast cancer: Further analyses indicated that trastuzumab-treated patients with high CMTM6 expressing HER2+ BC had a significant shorter overall survival (OS) and relapse free survival (RFS) than those with lower CMTM6 expressing HER2+ BC (Fig. 2E-F).